Oncology Institute Expands Partnership with Helios Clinical Research to Up Trial Access

 The Oncology Institute expands its partnership with Helios Clinical Research to enhance patient access to clinical trials and improve oncology care.

The Oncology Institute, Inc. (TOI) announced an expansion of its partnership with Helios Clinical Research to enhance clinical research capabilities in community oncology. This collaboration follows a successful initiative in Florida and aims to integrate clinical trials into routine patient care. TOI's CEO, Dr. Daniel Virnich, emphasized the benefits of the partnership, which include improved access to clinical trials for patients, streamlined processes for research sponsors, and a scalable infrastructure to support oncology clinicians. Both organizations are dedicated to promoting equity in oncology research by enrolling diverse patient populations. TOI, founded in 2007, serves over 1.8 million patients and is focused on providing high-quality, value-based cancer care across its extensive network of clinics.

Potential Positives

• Expansion of strategic partnership with Helios Clinical Research enhances TOI’s research capabilities and infrastructure.
• Increased access to clinical trials for patients leads to better treatment options and improved patient outcomes.
• Commitment to advancing health equity by enrolling diverse and underrepresented patient populations in clinical research.

Potential Negatives

• Expansion of partnership may indicate challenges in managing existing operations or a need to enhance research capabilities beyond current resources.
• Dependence on a third-party partner like Helios Clinical Research could pose risks to TOI's autonomy and control over its clinical trials.
• Potential scrutiny on the effectiveness and quality of care due to the integration of clinical research in community settings, which may raise questions about prioritization of patient care.

The Oncology Institute is expanding its strategic partnership with Helios Clinical Research to enhance clinical trial access and execution in community oncology.

This initiative will provide patients greater access to advanced therapies through clinical trials and improve overall care delivery.

The goals include integrating clinical research into patient care, improving trial performance, and ensuring health equity in oncology research.

The Oncology Institute was founded in 2007 and has since been dedicated to advancing value-based cancer care in community settings.

For more details, visit The Oncology Institute's official website at www.theoncologyinstitute.com.

TOI Insider Trading Activity

$TOI insiders have traded $TOI stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $TOI stock by insiders over the last 6 months:

• RICHARD A BARASCH purchased 1,358,448 shares for an estimated $1,415,095
• MARK L PACALA purchased 90,562 shares for an estimated $94,338
• BRAD HIVELY has made 3 purchases buying 309,056 shares for an estimated $59,433 and 0 sales.
• KAREN MARIE JOHNSON purchased 36,224 shares for an estimated $37,734
• DANIEL VIRNICH (Chief Executive Officer) purchased 22,640 shares for an estimated $23,584
• YALE PODNOS (Chief Medical Officer) purchased 9,056 shares for an estimated $9,433
• JEREMY CASTLE (Chief Operating Officer) purchased 9,056 shares for an estimated $9,433
• ROBERT ROSS CARTER (Chief Financial Officer) purchased 9,056 shares for an estimated $9,433

TOI Hedge Fund Activity

We have seen 13 institutional investors add shares of $TOI stock to their portfolio, and 11 decrease their positions in their most recent quarter

Here are some of the largest recent moves:

• FMR LLC removed 4,749,900 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,467,719
• KENT LAKE PR LLC removed 2,000,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $618,000
• FREEGULLIVER LLC added 412,578 shares (+219.3%) to their portfolio in Q4 2024, for an estimated $127,486
• TIFF ADVISORY SERVICES, LLC added 346,256 shares (+13.2%) to their portfolio in Q4 2024, for an estimated $106,993
• VIRTU FINANCIAL LLC added 131,759 shares (+inf%) to their portfolio in Q4 2024, for an estimated $40,713
• JANE STREET GROUP, LLC added 109,769 shares (+613.6%) to their portfolio in Q4 2024, for an estimated $33,918
• CITADEL ADVISORS LLC removed 91,337 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $28,223

https://www.nasdaq.com/articles/oncology-institute-expands-partnership-helios-clinical-research-enhance-access-clinical